Johnson & Johnson Statement on COVID-19 Vaccine (7/12)

Angie SzumlinskiNews

The company says the safety and well-being of the people who use our products is our number one priority. Rare cases of the neurological disorder, Guillain-Barré syndrome have been reported following vaccination with the Janssen COVID-19 vaccine. Most occurred within 42 days after vaccination. While the chance of having this occur is very low, Johnson & Johnson has updated its …